Educational Wellness Information Only
This platform provides peer-reviewed research summaries and educational content about peptides for wellness and optimization purposes. Nothing on this site is intended as medical advice, diagnosis, or treatment. We do not claim any peptide can diagnose, treat, cure, or prevent any disease. Always consult a licensed healthcare provider before beginning any wellness protocol.
Statements on this site have not been evaluated by the FDA. Compounded preparations are subject to applicable state and federal regulations. Availability and eligibility vary.
Lanreotide (Somatuline) vs Teriparatide (Forteo)
An educational, source-based comparison of Lanreotide (Somatuline) and Teriparatide (Forteo) — how each peptide works, what it's researched for, and what to know before going deeper.
Long-acting somatostatin analog for acromegaly and NETs.
Cyclic octapeptide somatostatin analog with high affinity for SSTR2 and SSTR5. Suppresses GH secretion and slows progression of gastroenteropancreatic neuroendocrine tumors.
- Acromegaly
- Gastroenteropancreatic NETs
- Carcinoid syndrome
- • FDA-approved.
- • Monitor gallbladder, glucose, and thyroid function.
Recombinant PTH(1-34) for severe osteoporosis.
Recombinant fragment of parathyroid hormone (amino acids 1–34). Intermittent dosing stimulates osteoblast activity more than osteoclasts, producing net bone formation and increased bone mineral density.
- Postmenopausal osteoporosis
- Male osteoporosis
- Glucocorticoid-induced osteoporosis
- • FDA-approved.
- • Lifetime use limited to 2 years; transient hypercalcemia possible.
Lanreotide (Somatuline) vs Teriparatide (Forteo) — Key differences
- Class: Lanreotide (Somatuline) is classified as Somatostatin Analog · Oncology, while Teriparatide (Forteo) is Parathyroid Hormone · Anabolic Bone.
- Primary research focus: Lanreotide (Somatuline) — acromegaly; Teriparatide (Forteo) — postmenopausal osteoporosis.
- Tag: FDA-Approved · Endocrine vs FDA-Approved · Bone.